Ayr Wellness Announces Mutual Termination of Proposed Acquisition of Dispensary 33
MIAMI – Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF), a U.S. multi-state cannabis operator, announced the termination of the Company’s previously announced proposed acquisition of the equity interests of Gentle Ventures, LLC d/b/a Dispensary 33, and certain of its affiliates that collectively own and operate two licensed retail dispensaries in Chicago, Illinois.
Following the mutual termination, Ayr will no longer be required to pay the previously announced purchase consideration of $55 million upfront, including $12 million of cash, $3 million of sellers notes and $40 million of stock.
“The cannabis market has changed significantly in the 15 months since we agreed to acquire Dispensary 33. Both parties have acknowledged this reality and engaged in good faith dialogue as we came to the mutual decision to terminate the proposed arrangement,” said David Goubert, President at Ayr. “We are focused on optimizing our business and will prioritize our efforts in markets where we can build meaningful depth and drive strong revenue and cash flow in the near term. Additional plans for optimization include implementation of operating efficiencies, lowering costs across our business, and reorienting our investments into the markets, segments and activities that are most impactful for our growth and profitability.”
Certain information contained in this news release may be forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by the use of words such as “target”, “expect”, “anticipate”, “believe”, “foresee”, “could”, “would”, “estimate”, “goal”, “outlook”, “intend”, “plan”, “seek”, “will”, “may”, “tracking”, “pacing” and “should” and similar expressions or words suggesting future outcomes. This news release includes forward-looking information and statements pertaining to, among other things, Ayr’s future growth plans. Numerous risks and uncertainties could cause the actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: anticipated strategic, operational and competitive benefits may not be realized; events or series of events, including in connection with COVID-19, may cause business interruptions; required regulatory approvals may not be obtained in a timely manner or at all; inflationary pressures may increase input costs; supply chain issues may hamper production and distribution; scientific research regarding cannabis is still in its early stages and is subject to change as further research is completed; state laws may restrict or prevent inter-state commerce in cannabis products; acquisitions may not be able to be completed on satisfactory terms or at all; and Ayr may not be able to raise needed additional debt or equity capital. Among other things, Ayr has assumed that its businesses will operate as anticipated, that it will be able to complete acquisitions on reasonable terms, and that all required regulatory approvals will be obtained on satisfactory terms and within expected time frames. Forward-looking estimates and assumptions involve known and unknown risks and uncertainties that may cause actual results to differ materially. While Ayr believes there is a reasonable basis for these assumptions, such estimates may not be met. These estimates represent forward-looking information. Actual results may vary and differ materially from the estimates.
(This information is primarily sourced from Ayr Wellness Inc. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
New York Bill Advances to Cover Medical Cannabis Under State-Funded Insurance Programs
NEW YORK-- New York state lawmakers are pushing forward with a measure that could bring significant relief to patients seeking medical cannabis treatment. The proposed bill, which advanced easily out of a state Assembly committee ...
Canopy Growth Corp. Ordered to Pay C$15 Million in Arbitration Ruling
LOS ANGELES-- Canopy Growth Corp., a major player in the cannabis industry based in Canada, has been hit with a C$15 million penalty by an arbitration tribunal for breach of contract, according to a regulatory ...
Curaleaf to Close NJ Cannabis Cultivation Facility, Resulting in Layoffs
LOS ANGELES-- Curaleaf, a cannabis giant based in Massachusetts, has announced that it will close its cannabis cultivation facility in Bellmawr, New Jersey. The closure will reportedly result in the loss of up to 40 ...